Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.00 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | reachable by antibody | 0.45 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | no papers tie it to Parkinson's yet | 1.00 |
| pathways Reactome | 3 pathways; mostly protein handling | 0.90 |
No case: the score is under the bar. Receipt 16144
Sealed predictions
- CAND1 in dopamine neurons, braak+0.09 (p 0.820) → -0.06 (p 0.874)receipt 16151
Swarm cases
receipt 16151: CAND1 in dopamine neurons, braak
- power
- full sample -0.00 (p 0.990, n 18), 95% CI -0.47 to +0.46. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.01 (p 0.983, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.01 (p 0.956, n 18). could be the mix.
- skeptic
- leave-one-out range -0.14 to +0.10, sign flips 6; without severely affected donors -0.00 (p 0.990, n 18). fragile.
- cell type
- strongest in oligodendrocytes: +0.64 (p 0.0044, n 18) vs -0.00 in dopamine neurons. proposing oligodendrocytes.
- axis
- no measure beats "tracks Braak Lewy-body stage" for CAND1 in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up CAND1 · oligodendrocytes · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) +0.23 p 0.424 (needs p < 1.4e-4)
Receipts
loading the receipts